Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Rigel Pharmaceuticals is a biotech company focused on developing therapies for hematologic disorders and cancer. Its core products include FDA-approved treatments for immune thrombocytopenia, AML with IDH1 mutations, and RET fusion-positive cancers. The company leverages strategic collaborations, licensing, and a commercial infrastructure to develop, manufacture, and market targeted therapies globally, emphasizing innovation in oncology and hematology.
This description was generated via AI from an annual report. Updated about 1 year ago.